huSLC6A19 Mouse
製品名
huSLC6A19 Mouse
製品ID
C002000
系統名
C57BL/6NCya-Slc6a19tm1(hSLC6A19)/Cya
背景情報
C57BL/6NCya
状況
このマウス系統を論文で使用する場合は、「huSLC6A19 Mouse（カタログ番号C002000）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
遺伝子名
遺伝子別名
HND, B0AT1
NCBI ID
染色体
Chr 5
MGI ID
さらに
系統詳細
The SLC6A19 gene encodes B0AT1, a sodium-dependent neutral amino acid transporter. Operating as the primary apical transporter, B0AT1 mediates the Na+-dependent (chloride-independent) uptake of most neutral amino acids across epithelial membranes to facilitate intestinal absorption and renal reabsorption [1]. This process requires essential accessory proteins: ACE2 in the intestine and collectrin (CLTRN) in the kidney for proper trafficking and functional activity. Primarily expressed in the small intestine and renal proximal tubules—with secondary expression in the pancreas, liver, and brain ependymal cells—B0AT1 is vital for systemic amino acid homeostasis. Mutations in this gene result in Hartnup disorder, an autosomal-recessive condition defined by neutral aminoaciduria and tryptophan/niacin deficiencies, which may manifest as pellagra-like rashes, ataxia, or neuropsychiatric issues such as ADHD [2]. Interestingly, SLC6A19 is now a therapeutic target. Pharmacological inhibition is being studied to manage phenylketonuria (PKU) by promoting urinary amino acid excretion [3]. Furthermore, inhibiting or deleting SLC6A19 mimics the effects of dietary protein restriction, offering metabolic benefits such as improved glucose tolerance, obesity prevention, and elevated levels of FGF21 and GLP-1 [4].
The huSLC6A19 mouse model was generated by replacing the sequences from the ATG start codon to 3'UTR of the endogenous mouse Slc6a19 gene with the sequences from the ATG start codon to 3'UTR of the human SLC6A19 gene. This model is applicable to research on metabolic disorders such as Hartnup disease, phenylketonuria (PKU), and obesity, as well as to the screening, development, and safety evaluation of SLC6A19-targeted drugs.
参考文献
Xu J, Hu Z, Dai L, Yadav A, Jiang Y, Bröer A, Gardiner MG, McLeod M, Yan R, Bröer S. Molecular basis of inhibition of the amino acid transporter B0AT1 (SLC6A19). Nat Commun. 2024 Aug 22;15(1):7224.
Kravetz Z, Schmidt-Kastner R. New aspects for the brain in Hartnup disease based on mining of high-resolution cellular mRNA expression data for SLC6A19. IBRO Neurosci Rep. 2023 Mar 25;14:393-397.
Wobst HJ, Viader A, Muncipinto G, Hollibaugh R, van Kalken D, Burkhart CT, Cantin SM, Bates RM, Regimbald-Dumas Y, Gross L, Antalek MT, Zweig JE, Wu F, Rettenmaier TJ, Labenski MT, Pullen N, Blanchette HS, Henderson JL, Weng HH, Vaughn TA, Brown DG, Throup JP, Barrish JC. SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine. JCI Insight. 2024 Nov 8;9(21):e182876.
Javed K, Cheng Q, Carroll AJ, Truong TT, Bröer S. Development of Biomarkers for Inhibition of SLC6A19 (B⁰AT1)-A Potential Target to Treat Metabolic Disorders. Int J Mol Sci. 2018 Nov 14;19(11):3597.
系統作製戦略
The sequences from the start codon to 3'UTR of the endogenous mouse Slc6a19 gene were replaced with the sequences from the start codon to 3'UTR of the human SLC6A19 gene. The expression of mouse Slc6a19os may be affected by this KI region.
Figure 1. Gene editing strategy of huSLC6A19 mice.
適用分野
Screening, development, and preclinical evaluation of SLC6A19-targeted drugs;
Research on the Hartnup disorder;
Research on the phenylketonuria (PKU);
Research on the pathological mechanism and treatment methods of metabolic diseases, such as obesity.
お問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。